2021
DOI: 10.1111/ane.13575
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Guillain‐Barre syndrome following COVID‐19 vaccines (GBSfCV19v) is a reported adverse effect that remains unclear. We present a structured review based on two case reports of GBSfCV19v, a systematic review, and Vaccine Adverse Event Reporting System (VAERS) analysis to estimate the risk and describe the clinical characteristics (CC) of these events. We've searched on MEDLINE and Embase, from the inception to May 20, 2021, using the keywords: “Guillain barre syndrome” and cross‐referenced with “covid‐19 vaccine… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0
1

Year Published

2022
2022
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(18 citation statements)
references
References 7 publications
0
17
0
1
Order By: Relevance
“…However, there are also reports that suggest that there is no increased risk of relapse activity among vaccinated patients with MS and that benefits outweigh the potential dangers of COVID‐19 vaccination [ 54 , 55 ]. Acute CNS or PNS demyelination is a known but infrequent complication of other vaccines and has also been observed in close temporal relation to SARS‐CoV‐2 vaccination [ 56 , 57 ]. However, individual case reports are not suitable to establish any causality.…”
Section: Risk–benefit Profile Of Sars‐cov‐2 Vaccination: Neurological...mentioning
confidence: 99%
“…However, there are also reports that suggest that there is no increased risk of relapse activity among vaccinated patients with MS and that benefits outweigh the potential dangers of COVID‐19 vaccination [ 54 , 55 ]. Acute CNS or PNS demyelination is a known but infrequent complication of other vaccines and has also been observed in close temporal relation to SARS‐CoV‐2 vaccination [ 56 , 57 ]. However, individual case reports are not suitable to establish any causality.…”
Section: Risk–benefit Profile Of Sars‐cov‐2 Vaccination: Neurological...mentioning
confidence: 99%
“…Symptoms like paresthesia and difficulty in moving after COVID-19 vaccination should not be missed, since there have been several reports of patients presenting with the same symptoms after vaccination. GBS has been reported to occur following various types of Covid-19 vaccines so far (8), however, to the author's awareness, GBS symptoms following Sinopharm COVID-19 vaccine have been reported infrequently.…”
Section: Discussionmentioning
confidence: 83%
“…Symptoms such as paresthesia and difficulty in moving after COVID‐19 vaccination should not be missed, since there have been several reports of patients presenting with the same symptoms after vaccination. GBS has been reported to occur following various types of COVID‐19 vaccines so far, 9 however, to the author's awareness, GBS symptoms following Sinopharm COVID‐19 vaccine have been reported infrequently.…”
Section: Discussionmentioning
confidence: 85%